desloratadine (redirected from Claramax)

desloratadine

[des′lärat′ädēn]

a nonsedating antihistamine (H₁ receptor antagonist) used for treatment of allergic rhinitis and chronic idiopathic urticaria. It is administered orally.

---

desloratadine

Clarinex, Clarinex Reditabs, Neoclarityn (UK)

Pharmacologic class: Peripherally selective piperidine, selective histamine₁-receptor antagonist

Therapeutic class: Antihistamine (nonsedating, second generation)

Pregnancy risk category C

Action

Suppresses histamine release at peripheral histamine₁-receptor sites

Availability

Syrup: 2.5 mg/5 ml

Tablets: 5 mg

⊘Indications and dosages

➣ Seasonal and perennial allergic rhinitis; chronic idiopathic urticaria and allergies caused by indoor and outdoor allergens; pruritus; to reduce number and size of hives

Adults and children ages 12 and older: 5 mg/day P.O.

Children ages 6 to 11: 1 tsp (2.5 mg/5 ml syrup) P.O. once daily

Children ages 12 months to 5 years: ½ tsp (1.25 mg in 2.5 ml syrup) P.O. once daily

Children ages 6 to 11 months: 2 ml (1 mg syrup) P.O. once daily

Dosage adjustment

• Hepatic or renal impairment

Contraindications

• Hypersensitivity to drug, its components, or loratadine

Precautions

Use cautiously in:
• renal or hepatic impairment
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 12 (safety and efficacy not established, except syrup).

Administration

• Give with or without food.

Route	Onset	Peak	Duration
P.O.	1 hr	3 hr	24 hr

Adverse reactions

CNS: dizziness, drowsiness, fatigue, headache

CV: tachycardia, palpitations

EENT: pharyngitis, dry throat

GI: nausea, dyspepsia, dry mouth

GU: dysmenorrhea

Musculoskeletal: myalgia

Other: flulike symptoms, hypersensitivity reaction

Interactions

Drug-diagnostic tests. Bilirubin, hepatic enzymes: increased values

Skin tests: interference with positive reaction to dermal reactivity indicators

Patient monitoring

• Monitor hepatic and renal function test results.

Patient teaching

• Tell patient he may take drug with or without food.
• Instruct patient to report rapid heartbeat, shortness of breath, rash, persistent flulike symptoms, or muscle ache.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests mentioned above.